Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients
This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in asses...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2005-02, Vol.30 (2), p.405-416 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 416 |
|---|---|
| container_issue | 2 |
| container_start_page | 405 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 30 |
| creator | RUSH, A. John TRIVEDI, Madhukar H DUNNER, David L GELENBERG, Alan J KOCSIS, James H NEMEROFF, Charles B FAWCETT, Jan THASE, Michael E RUSSELL, James M JODY, Darlene N BORIAN, Frances E KELLER, Martin B CARMODY, Thomas J IBRAHIM, Hisham M MARKOWITZ, John C KEITNER, Gabor I KORNSTEIN, Susan G ARNOW, Bruce KLEIN, Daniel N MANBER, Rachel |
| description | This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-I, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a > or =50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-I score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-I), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-I), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR16), 73% (PGI-I), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30=32%, QIDS-SR16=28%, PGI-I=22%, HDRS17=30%), for CBASP (IDS-SR30=32%, QIDS-SR16=30%, PGI-I=21%, HDRS17=32%), and for the combination (IDS-SR30=52%, QIDS-SR16=50%, PGI-I=25%, HDRS17=49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings. |
| doi_str_mv | 10.1038/sj.npp.1300614 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67360115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67360115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-7acd15413631569dd1e1fc33aa956bc9471bc9386e56dbd61245b6e153223f563</originalsourceid><addsrcrecordid>eNpd0c-L1DAUB_AgijuOXr0pQdCTHfOaJm29yez6A1YXdlbYW8mkr7sZ2qQm6cL4z_ivmmEqA14SCJ-895IvIS-BrYDx6kPYrew4roAzJqF4RBZQFiyTvLh9TBasqnkGnN-ekWch7BgDUcrqKTkDIcqKsWpB_myw77JrHJ2P2NJzHD2GYB6QbvbDGN1Av6MKUzr8SDdog4nmwcQ9jS7ZiDoae0fX98reITWWKnqtbOsG8xvb93TtbPSu71PhG29UT12XrHfWaNX3-3_dDvSHs2PY63sXjaZXUxxVNGhjeE6edKoP-GLel-Tn54ub9dfs8urLt_Wny0wXkMesVLoFUQCXHISs2xYQOs25UrWQW10XJaSVVxKFbLethLwQW4kgeJ7zTki-JO-OdUfvfk0YYjOYoLHvlUU3hUaWXDJIfkne_Ad3bvI2zdbkuch5yesDWh2R9i4Ej10zejMov2-ANYfcmrBrUm7NnFu68HquOm0HbE98DiqBtzNQIX1e55XVJpyclKws4fCOV0dnVUypncDc6C8n0K1m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225237395</pqid></control><display><type>article</type><title>Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>RUSH, A. John ; TRIVEDI, Madhukar H ; DUNNER, David L ; GELENBERG, Alan J ; KOCSIS, James H ; NEMEROFF, Charles B ; FAWCETT, Jan ; THASE, Michael E ; RUSSELL, James M ; JODY, Darlene N ; BORIAN, Frances E ; KELLER, Martin B ; CARMODY, Thomas J ; IBRAHIM, Hisham M ; MARKOWITZ, John C ; KEITNER, Gabor I ; KORNSTEIN, Susan G ; ARNOW, Bruce ; KLEIN, Daniel N ; MANBER, Rachel</creator><creatorcontrib>RUSH, A. John ; TRIVEDI, Madhukar H ; DUNNER, David L ; GELENBERG, Alan J ; KOCSIS, James H ; NEMEROFF, Charles B ; FAWCETT, Jan ; THASE, Michael E ; RUSSELL, James M ; JODY, Darlene N ; BORIAN, Frances E ; KELLER, Martin B ; CARMODY, Thomas J ; IBRAHIM, Hisham M ; MARKOWITZ, John C ; KEITNER, Gabor I ; KORNSTEIN, Susan G ; ARNOW, Bruce ; KLEIN, Daniel N ; MANBER, Rachel</creatorcontrib><description>This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-I, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a > or =50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-I score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-I), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-I), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR16), 73% (PGI-I), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30=32%, QIDS-SR16=28%, PGI-I=22%, HDRS17=30%), for CBASP (IDS-SR30=32%, QIDS-SR16=30%, PGI-I=21%, HDRS17=32%), and for the combination (IDS-SR30=52%, QIDS-SR16=50%, PGI-I=25%, HDRS17=49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/sj.npp.1300614</identifier><identifier>PMID: 15578008</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Antidepressive Agents, Second-Generation - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Cognitive Therapy ; Combined Modality Therapy ; Depression ; Depressive Disorder - drug therapy ; Depressive Disorder - psychology ; Depressive Disorder - therapy ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Mood disorders ; Outpatients ; Psychiatric Status Rating Scales ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Self-Assessment ; Treatment Outcome ; Triazoles - therapeutic use</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2005-02, Vol.30 (2), p.405-416</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Feb 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-7acd15413631569dd1e1fc33aa956bc9471bc9386e56dbd61245b6e153223f563</citedby><cites>FETCH-LOGICAL-c412t-7acd15413631569dd1e1fc33aa956bc9471bc9386e56dbd61245b6e153223f563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16607716$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15578008$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUSH, A. John</creatorcontrib><creatorcontrib>TRIVEDI, Madhukar H</creatorcontrib><creatorcontrib>DUNNER, David L</creatorcontrib><creatorcontrib>GELENBERG, Alan J</creatorcontrib><creatorcontrib>KOCSIS, James H</creatorcontrib><creatorcontrib>NEMEROFF, Charles B</creatorcontrib><creatorcontrib>FAWCETT, Jan</creatorcontrib><creatorcontrib>THASE, Michael E</creatorcontrib><creatorcontrib>RUSSELL, James M</creatorcontrib><creatorcontrib>JODY, Darlene N</creatorcontrib><creatorcontrib>BORIAN, Frances E</creatorcontrib><creatorcontrib>KELLER, Martin B</creatorcontrib><creatorcontrib>CARMODY, Thomas J</creatorcontrib><creatorcontrib>IBRAHIM, Hisham M</creatorcontrib><creatorcontrib>MARKOWITZ, John C</creatorcontrib><creatorcontrib>KEITNER, Gabor I</creatorcontrib><creatorcontrib>KORNSTEIN, Susan G</creatorcontrib><creatorcontrib>ARNOW, Bruce</creatorcontrib><creatorcontrib>KLEIN, Daniel N</creatorcontrib><creatorcontrib>MANBER, Rachel</creatorcontrib><title>Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-I, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a > or =50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-I score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-I), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-I), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR16), 73% (PGI-I), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30=32%, QIDS-SR16=28%, PGI-I=22%, HDRS17=30%), for CBASP (IDS-SR30=32%, QIDS-SR16=30%, PGI-I=21%, HDRS17=32%), and for the combination (IDS-SR30=52%, QIDS-SR16=50%, PGI-I=25%, HDRS17=49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Cognitive Therapy</subject><subject>Combined Modality Therapy</subject><subject>Depression</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - psychology</subject><subject>Depressive Disorder - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Outpatients</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Self-Assessment</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0c-L1DAUB_AgijuOXr0pQdCTHfOaJm29yez6A1YXdlbYW8mkr7sZ2qQm6cL4z_ivmmEqA14SCJ-895IvIS-BrYDx6kPYrew4roAzJqF4RBZQFiyTvLh9TBasqnkGnN-ekWch7BgDUcrqKTkDIcqKsWpB_myw77JrHJ2P2NJzHD2GYB6QbvbDGN1Av6MKUzr8SDdog4nmwcQ9jS7ZiDoae0fX98reITWWKnqtbOsG8xvb93TtbPSu71PhG29UT12XrHfWaNX3-3_dDvSHs2PY63sXjaZXUxxVNGhjeE6edKoP-GLel-Tn54ub9dfs8urLt_Wny0wXkMesVLoFUQCXHISs2xYQOs25UrWQW10XJaSVVxKFbLethLwQW4kgeJ7zTki-JO-OdUfvfk0YYjOYoLHvlUU3hUaWXDJIfkne_Ad3bvI2zdbkuch5yesDWh2R9i4Ej10zejMov2-ANYfcmrBrUm7NnFu68HquOm0HbE98DiqBtzNQIX1e55XVJpyclKws4fCOV0dnVUypncDc6C8n0K1m</recordid><startdate>20050201</startdate><enddate>20050201</enddate><creator>RUSH, A. John</creator><creator>TRIVEDI, Madhukar H</creator><creator>DUNNER, David L</creator><creator>GELENBERG, Alan J</creator><creator>KOCSIS, James H</creator><creator>NEMEROFF, Charles B</creator><creator>FAWCETT, Jan</creator><creator>THASE, Michael E</creator><creator>RUSSELL, James M</creator><creator>JODY, Darlene N</creator><creator>BORIAN, Frances E</creator><creator>KELLER, Martin B</creator><creator>CARMODY, Thomas J</creator><creator>IBRAHIM, Hisham M</creator><creator>MARKOWITZ, John C</creator><creator>KEITNER, Gabor I</creator><creator>KORNSTEIN, Susan G</creator><creator>ARNOW, Bruce</creator><creator>KLEIN, Daniel N</creator><creator>MANBER, Rachel</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20050201</creationdate><title>Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients</title><author>RUSH, A. John ; TRIVEDI, Madhukar H ; DUNNER, David L ; GELENBERG, Alan J ; KOCSIS, James H ; NEMEROFF, Charles B ; FAWCETT, Jan ; THASE, Michael E ; RUSSELL, James M ; JODY, Darlene N ; BORIAN, Frances E ; KELLER, Martin B ; CARMODY, Thomas J ; IBRAHIM, Hisham M ; MARKOWITZ, John C ; KEITNER, Gabor I ; KORNSTEIN, Susan G ; ARNOW, Bruce ; KLEIN, Daniel N ; MANBER, Rachel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-7acd15413631569dd1e1fc33aa956bc9471bc9386e56dbd61245b6e153223f563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Cognitive Therapy</topic><topic>Combined Modality Therapy</topic><topic>Depression</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - psychology</topic><topic>Depressive Disorder - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Outpatients</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Self-Assessment</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUSH, A. John</creatorcontrib><creatorcontrib>TRIVEDI, Madhukar H</creatorcontrib><creatorcontrib>DUNNER, David L</creatorcontrib><creatorcontrib>GELENBERG, Alan J</creatorcontrib><creatorcontrib>KOCSIS, James H</creatorcontrib><creatorcontrib>NEMEROFF, Charles B</creatorcontrib><creatorcontrib>FAWCETT, Jan</creatorcontrib><creatorcontrib>THASE, Michael E</creatorcontrib><creatorcontrib>RUSSELL, James M</creatorcontrib><creatorcontrib>JODY, Darlene N</creatorcontrib><creatorcontrib>BORIAN, Frances E</creatorcontrib><creatorcontrib>KELLER, Martin B</creatorcontrib><creatorcontrib>CARMODY, Thomas J</creatorcontrib><creatorcontrib>IBRAHIM, Hisham M</creatorcontrib><creatorcontrib>MARKOWITZ, John C</creatorcontrib><creatorcontrib>KEITNER, Gabor I</creatorcontrib><creatorcontrib>KORNSTEIN, Susan G</creatorcontrib><creatorcontrib>ARNOW, Bruce</creatorcontrib><creatorcontrib>KLEIN, Daniel N</creatorcontrib><creatorcontrib>MANBER, Rachel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUSH, A. John</au><au>TRIVEDI, Madhukar H</au><au>DUNNER, David L</au><au>GELENBERG, Alan J</au><au>KOCSIS, James H</au><au>NEMEROFF, Charles B</au><au>FAWCETT, Jan</au><au>THASE, Michael E</au><au>RUSSELL, James M</au><au>JODY, Darlene N</au><au>BORIAN, Frances E</au><au>KELLER, Martin B</au><au>CARMODY, Thomas J</au><au>IBRAHIM, Hisham M</au><au>MARKOWITZ, John C</au><au>KEITNER, Gabor I</au><au>KORNSTEIN, Susan G</au><au>ARNOW, Bruce</au><au>KLEIN, Daniel N</au><au>MANBER, Rachel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>2005-02-01</date><risdate>2005</risdate><volume>30</volume><issue>2</issue><spage>405</spage><epage>416</epage><pages>405-416</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>This study evaluated and compared the performance of three self-report measures: (1) 30-item Inventory of Depressive Symptomatology-Self-Report (IDS-SR30); (2) 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16); and (3) Patient Global Impression-Improvement (PGI-I) in assessing clinical outcomes in depressed patients during a 12-week, acute phase, randomized, controlled trial comparing nefazodone, cognitive-behavioral analysis system of psychotherapy (CBASP), and the combination in the treatment of chronic depression. The IDS-SR30, QIDS-SR16, PGI-I, and the 24-item Hamilton Depression Rating Scale (HDRS24) ratings were collected at baseline and at weeks 1-4, 6, 8, 10, and 12. Response was defined a priori as a > or =50% reduction in baseline total score for the IDS-SR30 or for the QIDS-SR16 or as a PGI-I score of 1 or 2 at exit. Overall response rates (LOCF) to nefazodone were 41% (IDS-SR30), 45% (QIDS-SR16), 53% (PCI-I), and 47% (HDRS17). For CBASP, response rates were 41% (IDS-SR30), 45% (QIDS-SR16), 48% (PGI-I), and 46% (HDRS17). For the combination, response rates were 68% (IDS-SR30 and QIDS-SR16), 73% (PGI-I), and 76% (HDRS17). Similarly, remission rates were comparable for nefazodone (IDS-SR30=32%, QIDS-SR16=28%, PGI-I=22%, HDRS17=30%), for CBASP (IDS-SR30=32%, QIDS-SR16=30%, PGI-I=21%, HDRS17=32%), and for the combination (IDS-SR30=52%, QIDS-SR16=50%, PGI-I=25%, HDRS17=49%). Both the IDS-SR30 and QIDS-SR16 closely mirrored and confirmed findings based on the HDRS24. These findings raise the possibility that these two self-reports could provide cost- and time-efficient substitutes for clinician ratings in treatment trials of outpatients with nonpsychotic MDD without cognitive impairment. Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings.</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>15578008</pmid><doi>10.1038/sj.npp.1300614</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 2005-02, Vol.30 (2), p.405-416 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67360115 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult Adult and adolescent clinical studies Aged Antidepressive Agents, Second-Generation - therapeutic use Biological and medical sciences Chronic Disease Cognitive Therapy Combined Modality Therapy Depression Depressive Disorder - drug therapy Depressive Disorder - psychology Depressive Disorder - therapy Female Humans Male Medical sciences Middle Aged Mood disorders Outpatients Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Self-Assessment Treatment Outcome Triazoles - therapeutic use |
| title | Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T04%3A22%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Self-Reported%20Depressive%20Symptom%20Measures:%20Sensitivity%20to%20Detecting%20Change%20in%20a%20Randomized,%20Controlled%20Trial%20of%20Chronically%20Depressed,%20Nonpsychotic%20Outpatients&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=RUSH,%20A.%20John&rft.date=2005-02-01&rft.volume=30&rft.issue=2&rft.spage=405&rft.epage=416&rft.pages=405-416&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/sj.npp.1300614&rft_dat=%3Cproquest_cross%3E67360115%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225237395&rft_id=info:pmid/15578008&rfr_iscdi=true |